Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2012
    Antiparkinsonian Effects of T-type Calcium Channel Inhibitors

    Objective/Rationale:
    Parkinson’s disease is associated with changes in the electrical activity of nerve cells in the basal ganglia and thalamus, including the emergence of abnormal burst discharges...

  • Rapid Response Innovation Awards, 2012
    A Genetic Strategy to Restore Impaired Noradrenergic Function by Increasing Expression of Noradrenergic Phenotypes in the Locus Coeruleus in Parkinson’s Disease Pre-clinical Models

    Objective/Rationale:
    Compelling evidence demonstrated that a dysfunction of the locus coeruleus (LC)-
    noradrenaline (NE) system in the brain not only contributes to alterations in
    cognitive and motor...

  • Rapid Response Innovation Awards, 2012
    Phosphorylated Alpha-synuclein Species as Biomarkers for Diagnosis and Progression in Parkinson’s disease

    Objective/Rationale:
    Diagnosis of Parkinson’s disease would be facilitated by the discovery of objective biomarkers for identifying it at early stages and differentiating it from other related...

  • MJFF Research Grant, 2012
    Using External Research Experts to Mine the 23andMe Parkinson’s Dataset

    Objective/Rationale:
    Currently at 23andMe we have whole-genome genotype data for 5,449 Parkinson’s disease (PD) patients and 110,853 healthy subjects. This is by far the largest cohort of case-control...

  • Therapeutics Development Initiative, 2012
    Targeting System-xc for the Treatment of Parkinson's Disease

    Objective/Rationale:
    Parkinson’s disease is characterized by the progressive loss of dopamine neurons in brain regions responsible for motor coordination and activity – disturbances of which are...

  • MJFF Research Grant, 2012
    Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia

    Objective/Rationale:
    The glutamate, serotonin and adenosine systems are interesting targets for pharmacological therapies in Parkinson´s disease. However, interventions addressed at single systems...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.